GT201400306A - Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida - Google Patents

Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida

Info

Publication number
GT201400306A
GT201400306A GT201400306A GT201400306A GT201400306A GT 201400306 A GT201400306 A GT 201400306A GT 201400306 A GT201400306 A GT 201400306A GT 201400306 A GT201400306 A GT 201400306A GT 201400306 A GT201400306 A GT 201400306A
Authority
GT
Guatemala
Prior art keywords
oxo
thiofencarboxamide
morfolinil
oxazolidin
chlorine
Prior art date
Application number
GT201400306A
Other languages
English (en)
Inventor
Beken Klaus
Neumann Heike
Mück Wolfgang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48782297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400306(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201400306A publication Critical patent/GT201400306A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A FORMAS DE ADMINISTRACIÓN FARMACÉUTICAS ADMINISTRABLES POR VÍA ORAL SÓLIDAS QUE COMPRENDEN 5-CLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORFOLINIL)FENIL]-1,3-OXAZOLIDIN-5-IL}METIL)-2-TIOFENCARBOXAMIDA (RIVAROXABÁN, COMPUESTO ACTIVO (I)), CARACTERIZADAS PORQUE SE LIBERA RÁPIDAMENTE UNA CANTIDAD PARCIAL DEL COMPUESTO ACTIVO (I) Y SE LIBERA UNA CANTIDAD PARCIAL DE UNA FORMA CONTROLADA (MODIFICADA, RETARDADA, POSPUESTA), Y A PROCEDIMIENTOS PARA SU PREPARACIÓN, A SU USO COMO MEDICAMENTOS Y A SU USO PARA LA PROFILAXIS, PROFILAXIS SECUNDARIA O TRATAMIENTO DE TRASTORNOS
GT201400306A 2012-07-03 2014-12-30 Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida GT201400306A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12174797 2012-07-03

Publications (1)

Publication Number Publication Date
GT201400306A true GT201400306A (es) 2015-08-25

Family

ID=48782297

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400306A GT201400306A (es) 2012-07-03 2014-12-30 Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida

Country Status (33)

Country Link
US (2) US20150125527A1 (es)
EP (1) EP2869814B1 (es)
JP (1) JP6166781B2 (es)
KR (1) KR20150027284A (es)
CN (1) CN104582684A (es)
AP (1) AP3756A (es)
AR (1) AR091621A1 (es)
AU (1) AU2013286068A1 (es)
BR (1) BR112015000043A2 (es)
CA (1) CA2878123A1 (es)
CL (1) CL2015000002A1 (es)
CO (1) CO7240379A2 (es)
CR (1) CR20150001A (es)
CU (1) CU20140152A7 (es)
DO (1) DOP2015000001A (es)
EA (1) EA025016B1 (es)
EC (1) ECSP14033581A (es)
ES (1) ES2574627T3 (es)
GT (1) GT201400306A (es)
HK (1) HK1209635A1 (es)
IL (1) IL236455A0 (es)
IN (1) IN2014DN11066A (es)
MA (1) MA37721B1 (es)
MX (1) MX2015000053A (es)
NZ (1) NZ703733A (es)
PE (1) PE20150189A1 (es)
PH (1) PH12014502833A1 (es)
SG (1) SG11201408420YA (es)
TN (1) TN2014000541A1 (es)
TW (1) TW201414508A (es)
UY (1) UY34856A (es)
WO (1) WO2014005934A1 (es)
ZA (1) ZA201500759B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
SI3377176T1 (sl) * 2016-02-23 2022-03-31 Morgandane Scientific, LLC Postopek zdravljenja pacientov s sočasnim dajanjem rivaroksabana in verapamila
CN107823166A (zh) * 2016-09-21 2018-03-23 齐鲁制药有限公司 一种利伐沙班片的制备方法
WO2020020790A1 (de) * 2018-07-24 2020-01-30 Bayer Aktiengesellschaft Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung
JOP20210019A1 (ar) * 2018-07-24 2021-01-24 Bayer Ag شكل جرعة صيدلانية تعطى عن طريق الفم ذات اطلاق مُعدّل
US10722486B2 (en) 2018-08-13 2020-07-28 Morgandane Scientific, LLC Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
JP7465157B2 (ja) * 2020-06-15 2024-04-10 沢井製薬株式会社 リバーロキサバン含有口腔内崩壊錠の製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US5160744A (en) 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
DE69920689T2 (de) * 1998-06-03 2005-02-24 Alza Corp., Mountain View Vorrichtungen zum Aufrechterhalten eines gewünschten therapeutischen Medikamenteneffekts über einen verlängerten Therapiezeitraum
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
JP2007504266A (ja) * 2003-09-02 2007-03-01 ファイザー・プロダクツ・インク ジプラシドンの持続放出剤形
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
CA2729979A1 (en) * 2008-07-08 2010-01-14 Ratiopharm Gmbh Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
MX2012015188A (es) * 2010-06-22 2013-05-20 Twi Pharmaceuticals Inc Composiciones de liberacion controlada con efecto de alimentos reducido.

Also Published As

Publication number Publication date
TN2014000541A1 (en) 2016-03-30
ECSP14033581A (es) 2015-12-31
IL236455A0 (en) 2015-02-26
AR091621A1 (es) 2015-02-18
US20140010876A1 (en) 2014-01-09
MA37721B1 (fr) 2016-12-30
CR20150001A (es) 2015-02-06
CU20140152A7 (es) 2015-10-27
DOP2015000001A (es) 2015-07-15
ZA201500759B (en) 2017-11-29
UY34856A (es) 2013-12-31
CA2878123A1 (en) 2014-01-09
MX2015000053A (es) 2015-04-10
BR112015000043A2 (pt) 2017-06-27
EP2869814A1 (de) 2015-05-13
JP2015521648A (ja) 2015-07-30
CO7240379A2 (es) 2015-04-17
NZ703733A (en) 2016-12-23
AP3756A (en) 2016-07-31
EA025016B1 (ru) 2016-11-30
EA201590142A1 (ru) 2015-06-30
EP2869814B1 (de) 2016-04-06
PH12014502833A1 (en) 2015-02-02
PE20150189A1 (es) 2015-01-31
MA37721A1 (fr) 2016-05-31
US20150125527A1 (en) 2015-05-07
AU2013286068A1 (en) 2015-01-29
JP6166781B2 (ja) 2017-07-19
AP2015008208A0 (en) 2015-01-31
IN2014DN11066A (es) 2015-09-25
SG11201408420YA (en) 2015-01-29
CL2015000002A1 (es) 2015-05-29
CN104582684A (zh) 2015-04-29
HK1209635A1 (en) 2016-04-08
ES2574627T3 (es) 2016-06-21
WO2014005934A1 (de) 2014-01-09
KR20150027284A (ko) 2015-03-11
TW201414508A (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
GT201400306A (es) Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
SV2009002857A (es) Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
BR112013025969A2 (pt) forma de dose unitária para administração oral
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201492050A1 (ru) Модуляторы ядерного транспорта и их применение
EA201500742A1 (ru) Защищенные от нецелевого использования фармацевтические композиции
CU20160007A7 (es) Derivados de 2((( oxadiazol/triazol/tetrazol/isoxazol) metil) fenil)-1-(heterociclil)-ona como inhibidores activos de autotaxina
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
BR112015009228A8 (pt) Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
CY1118327T1 (el) Χρηση ενος παραγωγου πυραζολιου στην αντιμετωπιση οξεων εξαρσεων χρονιας αποφρακτικης πνευμονοπαθειας
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
EA201491281A1 (ru) КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ
CO7380758A2 (es) Derivados de la 2-(morfolin-4-il)-3-(1-amino-3-trifluorometil-piridin-4-il)-5-(oxazol-3-il-2-ona)-pirimidina, activos como inhibidores pi3k mtor, composiciones farmacéuticas del mismo, y sus métodos de fabricación
ES2429422R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
BR112014009580A2 (pt) composição farmacêutica de omeprazol
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
BR112013030365A2 (pt) composições para administração percutânea de princípio ativo fisiologicamente
AR093252A1 (es) Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
PE20170201A1 (es) Formas de dosificacion farmaceutica
CU20150065A7 (es) Compuestos derivados de bencil 4-((2-(triazol-5-il)acetamido)metil)piperidin-1- carboxilato activos como inhibidores de autotaxina